Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge

In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three l...

Full description

Saved in:
Bibliographic Details
Published inNeuropharmacology Vol. 58; no. 3; pp. 632 - 639
Main Authors Fell, Matthew J., Katner, Jason S., Johnson, Bryan G., Khilevich, Albert, Schkeryantz, Jeffrey M., Perry, Kenneth W., Svensson, Kjell A.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.03.2010
Subjects
Online AccessGet full text

Cover

Loading…
Abstract In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three limbic brain regions. Ketamine (25 mg/kg) increased HA in the medial prefrontal cortex (mPFC), ventral hippocampus (vHipp) and the nucleus accumbens (NAc) shell. LY379268 administered alone was without effect on basal HA efflux in the mPFC or vHipp but modestly decreased HA efflux in the NAc shell. Administration of LY379268 (3 and 10 mg/kg) prior to ketamine significantly attenuated the HA response in the mPFC, vHipp and the NAc shell. The inhibitory effects of LY379268 in the mPFC were mimicked by the systemic administration of the mGlu2 receptor positive allosteric modulator CBiPES (60 mg/kg). Finally, local perfusion experiments revealed that the effects of LY379268 on ketamine evoked HA efflux appear to be mediated by mGlu2 receptors outside the PFC as the intra-mPFC perfusion of LY379268 (100 μM or 300 μM) failed to attenuate ketamine evoked increases in HA efflux. Together, these novel observations reveal an effect of ketamine on histaminergic transmission in limbic brain areas and provide further insight into the possible antipsychotic mechanism of action of mGlu2/3 receptor agonists.
AbstractList In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three limbic brain regions. Ketamine (25 mg/kg) increased HA in the medial prefrontal cortex (mPFC), ventral hippocampus (vHipp) and the nucleus accumbens (NAc) shell. LY379268 administered alone was without effect on basal HA efflux in the mPFC or vHipp but modestly decreased HA efflux in the NAc shell. Administration of LY379268 (3 and 10 mg/kg) prior to ketamine significantly attenuated the HA response in the mPFC, vHipp and the NAc shell. The inhibitory effects of LY379268 in the mPFC were mimicked by the systemic administration of the mGlu2 receptor positive allosteric modulator CBiPES (60 mg/kg). Finally, local perfusion experiments revealed that the effects of LY379268 on ketamine evoked HA efflux appear to be mediated by mGlu2 receptors outside the PFC as the intra-mPFC perfusion of LY379268 (100 microM or 300 microM) failed to attenuate ketamine evoked increases in HA efflux. Together, these novel observations reveal an effect of ketamine on histaminergic transmission in limbic brain areas and provide further insight into the possible antipsychotic mechanism of action of mGlu2/3 receptor agonists.
In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three limbic brain regions. Ketamine (25 mg/kg) increased HA in the medial prefrontal cortex (mPFC), ventral hippocampus (vHipp) and the nucleus accumbens (NAc) shell. LY379268 administered alone was without effect on basal HA efflux in the mPFC or vHipp but modestly decreased HA efflux in the NAc shell. Administration of LY379268 (3 and 10 mg/kg) prior to ketamine significantly attenuated the HA response in the mPFC, vHipp and the NAc shell. The inhibitory effects of LY379268 in the mPFC were mimicked by the systemic administration of the mGlu2 receptor positive allosteric modulator CBiPES (60 mg/kg). Finally, local perfusion experiments revealed that the effects of LY379268 on ketamine evoked HA efflux appear to be mediated by mGlu2 receptors outside the PFC as the intra-mPFC perfusion of LY379268 (100 μM or 300 μM) failed to attenuate ketamine evoked increases in HA efflux. Together, these novel observations reveal an effect of ketamine on histaminergic transmission in limbic brain areas and provide further insight into the possible antipsychotic mechanism of action of mGlu2/3 receptor agonists.
In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three limbic brain regions. Ketamine (25 mg/kg) increased HA in the medial prefrontal cortex (mPFC), ventral hippocampus (vHipp) and the nucleus accumbens (NAc) shell. LY379268 administered alone was without effect on basal HA efflux in the mPFC or vHipp but modestly decreased HA efflux in the NAc shell. Administration of LY379268 (3 and 10 mg/kg) prior to ketamine significantly attenuated the HA response in the mPFC, vHipp and the NAc shell. The inhibitory effects of LY379268 in the mPFC were mimicked by the systemic administration of the mGlu2 receptor positive allosteric modulator CBiPES (60 mg/kg). Finally, local perfusion experiments revealed that the effects of LY379268 on ketamine evoked HA efflux appear to be mediated by mGlu2 receptors outside the PFC as the intra-mPFC perfusion of LY379268 (100 kM or 300 kM) failed to attenuate ketamine evoked increases in HA efflux. Together, these novel observations reveal an effect of ketamine on histaminergic transmission in limbic brain areas and provide further insight into the possible antipsychotic mechanism of action of mGlu2/3 receptor agonists.
In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three limbic brain regions. Ketamine (25 mg/kg) increased HA in the medial prefrontal cortex (mPFC), ventral hippocampus (vHipp) and the nucleus accumbens (NAc) shell. LY379268 administered alone was without effect on basal HA efflux in the mPFC or vHipp but modestly decreased HA efflux in the NAc shell. Administration of LY379268 (3 and 10 mg/kg) prior to ketamine significantly attenuated the HA response in the mPFC, vHipp and the NAc shell. The inhibitory effects of LY379268 in the mPFC were mimicked by the systemic administration of the mGlu2 receptor positive allosteric modulator CBiPES (60 mg/kg). Finally, local perfusion experiments revealed that the effects of LY379268 on ketamine evoked HA efflux appear to be mediated by mGlu2 receptors outside the PFC as the intra-mPFC perfusion of LY379268 (100 microM or 300 microM) failed to attenuate ketamine evoked increases in HA efflux. Together, these novel observations reveal an effect of ketamine on histaminergic transmission in limbic brain areas and provide further insight into the possible antipsychotic mechanism of action of mGlu2/3 receptor agonists.In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three limbic brain regions. Ketamine (25 mg/kg) increased HA in the medial prefrontal cortex (mPFC), ventral hippocampus (vHipp) and the nucleus accumbens (NAc) shell. LY379268 administered alone was without effect on basal HA efflux in the mPFC or vHipp but modestly decreased HA efflux in the NAc shell. Administration of LY379268 (3 and 10 mg/kg) prior to ketamine significantly attenuated the HA response in the mPFC, vHipp and the NAc shell. The inhibitory effects of LY379268 in the mPFC were mimicked by the systemic administration of the mGlu2 receptor positive allosteric modulator CBiPES (60 mg/kg). Finally, local perfusion experiments revealed that the effects of LY379268 on ketamine evoked HA efflux appear to be mediated by mGlu2 receptors outside the PFC as the intra-mPFC perfusion of LY379268 (100 microM or 300 microM) failed to attenuate ketamine evoked increases in HA efflux. Together, these novel observations reveal an effect of ketamine on histaminergic transmission in limbic brain areas and provide further insight into the possible antipsychotic mechanism of action of mGlu2/3 receptor agonists.
Author Schkeryantz, Jeffrey M.
Khilevich, Albert
Perry, Kenneth W.
Katner, Jason S.
Fell, Matthew J.
Johnson, Bryan G.
Svensson, Kjell A.
Author_xml – sequence: 1
  givenname: Matthew J.
  surname: Fell
  fullname: Fell, Matthew J.
  email: Fell_matthew@lilly.com
– sequence: 2
  givenname: Jason S.
  surname: Katner
  fullname: Katner, Jason S.
– sequence: 3
  givenname: Bryan G.
  surname: Johnson
  fullname: Johnson, Bryan G.
– sequence: 4
  givenname: Albert
  surname: Khilevich
  fullname: Khilevich, Albert
– sequence: 5
  givenname: Jeffrey M.
  surname: Schkeryantz
  fullname: Schkeryantz, Jeffrey M.
– sequence: 6
  givenname: Kenneth W.
  surname: Perry
  fullname: Perry, Kenneth W.
– sequence: 7
  givenname: Kjell A.
  surname: Svensson
  fullname: Svensson, Kjell A.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19951716$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1u1DAURi1URKeFV0Be8bNI8E0cJ9kglQpapEpsYG05npsZD44dbKcVL8Ez4-kMVGJBV5blc4-vvu-MnDjvkBAKrAQG4t2udLgEP29VmMqKsb4EKBnwJ2QFXVsXLRP8hKwYq7qi7ll3Ss5i3DHGeAfdM3IKfd9AC2JFfl3oZG5VMt5RP9IJkxp8ymqj6cYuSU0qIX0zXdnlbUUDapyTD5HGZZ4DxoiRbk3MmHGYny2qiNQ4as00ZMUQVL4E3GR_pKO31t8Zt6FKL1n7HY-DequsRbfB5-TpqGzEF8fznHz79PHr5XVx8-Xq8-XFTaF5y1KBVc9F3QjW1tA13SBY3ba6qUCP48i1ELyqkQ9C8aHPHAPW6IEP7agRKgG8PievD945-B8LxiQnEzVaqxz6Jcq2rrO3Acjkq_-SFVR9B_Ve-fIILsOEazkHM6nwU_7JOgPvD4AOPsaAo9Qm3SefckpWApP7cuVOPpQr9-VKAMnul-7-Efz94_HRD4dRzKHeGgwyaoNO49rkTpNce_O45DchhMfH
CitedBy_id crossref_primary_10_1016_j_jemermed_2016_09_020
crossref_primary_10_1177_2045125311400779
crossref_primary_10_1016_j_eplepsyres_2013_10_009
crossref_primary_10_1016_j_neuroscience_2013_07_010
crossref_primary_10_1021_cn200008d
crossref_primary_10_1016_j_neuroscience_2011_07_034
crossref_primary_10_1371_journal_pone_0144017
crossref_primary_10_1152_jn_00462_2021
crossref_primary_10_1007_s13760_014_0407_7
crossref_primary_10_1038_npp_2013_290
crossref_primary_10_1016_j_neuroscience_2010_12_012
crossref_primary_10_3389_fnmol_2018_00383
crossref_primary_10_1016_j_neuropharm_2020_108072
crossref_primary_10_1038_nbt_2914
crossref_primary_10_1007_s11172_013_0123_0
crossref_primary_10_1016_j_neulet_2011_03_050
crossref_primary_10_1038_tp_2017_198
crossref_primary_10_1254_jphs_10022FP
crossref_primary_10_1016_j_neuropharm_2015_05_034
crossref_primary_10_1124_pr_119_019133
crossref_primary_10_1016_j_neuropharm_2011_06_007
crossref_primary_10_1124_jpet_110_172957
crossref_primary_10_1016_j_pbb_2017_05_004
crossref_primary_10_1007_s00702_020_02287_8
Cites_doi 10.1016/0920-9964(94)00034-6
10.1002/(SICI)1096-9861(20000403)419:2<205::AID-CNE5>3.0.CO;2-0
10.1016/j.neuropharm.2008.06.016
10.1124/jpet.108.136861
10.1523/JNEUROSCI.17-08-02921.1997
10.1016/0006-8993(87)90802-X
10.1016/0028-3908(90)90034-O
10.1038/sj.bjp.0702994
10.1016/S0014-2999(00)00269-7
10.1038/sj.npp.1300238
10.1016/0091-3057(94)90506-1
10.1002/cne.903110105
10.1038/nm1632
10.1016/j.euroneuro.2004.10.001
10.1016/S0006-8993(97)00255-2
10.1016/S0306-4522(02)00652-8
10.1093/bja/83.6.945
10.1046/j.1471-4159.1996.67010171.x
10.2174/1568007024606177
10.1007/s00213-007-0974-x
10.1002/syn.10043
10.1196/annals.1300.019
10.1126/science.281.5381.1349
10.1016/0006-3223(91)90290-3
10.1046/j.1460-9568.1999.00519.x
10.1016/S0014-2999(97)01435-0
10.1016/j.bcp.2004.07.034
10.1016/0028-3908(88)90189-X
10.1152/physrev.1991.71.1.1
10.1016/S0301-0082(00)00039-3
10.1016/S0006-8993(97)00932-3
10.1523/JNEUROSCI.18-12-04705.1998
10.1111/j.1460-9568.2005.04450.x
10.1111/j.1471-4159.2006.04002.x
10.1176/ajp.148.10.1301
ContentType Journal Article
Copyright 2009 Elsevier Ltd
Copyright 2009 Elsevier Ltd. All rights reserved.
Copyright 2009 Elsevier Ltd. All rights reserved.
Copyright_xml – notice: 2009 Elsevier Ltd
– notice: Copyright 2009 Elsevier Ltd. All rights reserved.
– notice: Copyright 2009 Elsevier Ltd. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7X8
DOI 10.1016/j.neuropharm.2009.11.014
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE

Neurosciences Abstracts
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-7064
EndPage 639
ExternalDocumentID 19951716
10_1016_j_neuropharm_2009_11_014
S0028390809003621
Genre Journal Article
GroupedDBID ---
--K
--M
-~X
.55
.GJ
.~1
0R~
123
1B1
1RT
1~.
1~5
29N
3O-
4.4
41~
457
4G.
53G
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AACTN
AADPK
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATCM
AAXLA
AAXUO
ABCQJ
ABFNM
ABFRF
ABIVO
ABJNI
ABMAC
ABXDB
ABYKQ
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
ADIYS
ADMUD
AEBSH
AEFWE
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AKRWK
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AQVPL
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
C45
CS3
DU5
EBS
EFJIC
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HMQ
HMT
HVGLF
HZ~
IHE
J1W
K-O
KOM
L7B
M2V
M34
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SEW
SNS
SPCBC
SPT
SSN
SSP
SSZ
T5K
TEORI
WUQ
X7M
XOL
ZGI
ZXP
~G-
AATTM
AAXKI
AAYWO
AAYXX
ABWVN
ACRPL
ACVFH
ADCNI
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AGRNS
AIGII
AIIUN
AKBMS
AKYEP
ANKPU
APXCP
BNPGV
CITATION
SSH
CGR
CUY
CVF
ECM
EIF
NPM
PKN
7TK
EFKBS
7X8
ID FETCH-LOGICAL-c470t-e29463560731858b60377c521cfff4c66423e4b6a4b96350105cb4b7fce126143
IEDL.DBID .~1
ISSN 0028-3908
1873-7064
IngestDate Thu Jul 10 23:58:24 EDT 2025
Sun Aug 24 04:11:12 EDT 2025
Wed Feb 19 01:49:00 EST 2025
Tue Jul 01 01:51:23 EDT 2025
Thu Apr 24 23:09:25 EDT 2025
Tue Apr 02 10:07:20 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords LY379268
mGlu2/3 receptors
Histamine
Ketamine
CBiPES
In vivo microdialysis
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
Copyright 2009 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c470t-e29463560731858b60377c521cfff4c66423e4b6a4b96350105cb4b7fce126143
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 19951716
PQID 21298134
PQPubID 23462
PageCount 8
ParticipantIDs proquest_miscellaneous_733858511
proquest_miscellaneous_21298134
pubmed_primary_19951716
crossref_citationtrail_10_1016_j_neuropharm_2009_11_014
crossref_primary_10_1016_j_neuropharm_2009_11_014
elsevier_sciencedirect_doi_10_1016_j_neuropharm_2009_11_014
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2010
2010-03-00
2010-Mar
20100301
PublicationDateYYYYMMDD 2010-03-01
PublicationDate_xml – month: 03
  year: 2010
  text: March 2010
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Neuropharmacology
PublicationTitleAlternate Neuropharmacology
PublicationYear 2010
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Moghaddam, Adams (bib18) 1998; 281
Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates. San Diego, Academic Press.
Wouterlood, Steinbusch, Luiten, Bol (bib35) 1987; 406
Fell, Johnson, Svensson, Schoepp (bib8) 2008; 326
Lorrain, Baccei, Bristow, Anderson, Varney (bib15) 2003; 117
Kishi, Tsumori, Ono, Yokota, Ishino, Yasui (bib12) 2000; 419
Faucard, Armand, Heron, Cochois, Schwartz, Arrang (bib7) 2006; 98
Patil, Zhang, Martenyi, Lowe, Jackson, Andreev, Avedisova, Bardenstein, Gurovich, Morozova, Mosolov, Neznanov, Reznik, Smulevich, Tochilov, Johnson, Monn, Schoepp (bib23) 2007; 13
Prell, Green, Kaufmann, Khandelwal, Morrishow, Kirch, Linnoila, Wyatt (bib25) 1995; 14
Moghaddam, Adams, Verma, Daly (bib17) 1997; 17
Spooren, Gasparini, van der Putten, Koller, Nakanishi, Kuhn (bib30) 2000; 397
Yang, Hatton (bib36) 1997; 773
Iwabuchi, Ito, Tashiro, Kato, Kano, Itoh, Iwata, Matsuoka, Sato, Yanai (bib10) 2005; 15
Javitt, Zukin (bib11) 1991; 148
Lindefors, Barati, O'Connor (bib14) 1997; 759
Parada-Turska, Turski (bib22) 1990; 29
Stevens, Kuramasu, Haas (bib31) 1999; 11
Swanson, Schoepp (bib32) 2003; 1003
Itoh, Oishi, Nishibori, Saeki (bib9) 1985; 235
Perry, Falcone, Fell, Ryder, Yu, Love, Katner, Gordon, Wade, Man, Nomikos, Phebus, Cauvin, Johnson, Jones, Hoffmann, Sandusky, Walter, Porter, Yang, Merchant, Shannon, Svensson (bib24) 2008; 55
Okakura-Mochizuki, Mochizuki, Yamamoto, Horii, Yamatodani (bib20) 1996; 67
Brown, Stevens, Haas (bib2) 2001; 63
Danysz, Wroblewski, Costa (bib5) 1988; 27
Ericson, Blomqvist, Kohler (bib6) 1991; 311
Kubota, Hirota, Yoshida, Takahashi, Ohkawa, Anzawa, Kushikata, Matsuki (bib13) 1999; 83
Schoepp (bib26) 2001; 299
Schoepp, Marek (bib27) 2002; 1
Danysz, Essmann, Bresink, Wilke (bib4) 1994; 48
Sherin, Elmquist, Torrealba, Saper (bib29) 1998; 18
Yonezawa, Kuroki, Kawahara, Tashiro, Uchimura (bib37) 1998; 341
Nakai, Kitamura, Hashimoto, Kajimoto, Nishino, Mita, Tanaka (bib19) 1991; 30
Westerink, Cremers, De Vries, Liefers, Tran, De Boer (bib33) 2002; 43
Lorrain, Schaffhauser, Campbell, Baccei, Correa, Rowe, Rodriguez, Anderson, Varney, Pinkerton, Vernier, Bristow (bib16) 2003; 28
Woolley, Pemberton, Bate, Corti, Jones (bib34) 2008; 196
Coyle (bib3) 2004; 68
Okamura, Yanai, Higuchi, Sakai, Iwata, Ido, Sasaki, Watanabe, Itoh (bib21) 2000; 129
Aggleton, Vann, Saunders (bib1) 2005; 22
Schwartz, Arrang, Garbarg, Pollard, Ruat (bib28) 1991; 71
Parada-Turska (10.1016/j.neuropharm.2009.11.014_bib22) 1990; 29
Yang (10.1016/j.neuropharm.2009.11.014_bib36) 1997; 773
Fell (10.1016/j.neuropharm.2009.11.014_bib8) 2008; 326
Prell (10.1016/j.neuropharm.2009.11.014_bib25) 1995; 14
Itoh (10.1016/j.neuropharm.2009.11.014_bib9) 1985; 235
Lindefors (10.1016/j.neuropharm.2009.11.014_bib14) 1997; 759
Schoepp (10.1016/j.neuropharm.2009.11.014_bib27) 2002; 1
Yonezawa (10.1016/j.neuropharm.2009.11.014_bib37) 1998; 341
Okamura (10.1016/j.neuropharm.2009.11.014_bib21) 2000; 129
Patil (10.1016/j.neuropharm.2009.11.014_bib23) 2007; 13
Kishi (10.1016/j.neuropharm.2009.11.014_bib12) 2000; 419
Kubota (10.1016/j.neuropharm.2009.11.014_bib13) 1999; 83
Aggleton (10.1016/j.neuropharm.2009.11.014_bib1) 2005; 22
Lorrain (10.1016/j.neuropharm.2009.11.014_bib15) 2003; 117
Sherin (10.1016/j.neuropharm.2009.11.014_bib29) 1998; 18
Westerink (10.1016/j.neuropharm.2009.11.014_bib33) 2002; 43
Ericson (10.1016/j.neuropharm.2009.11.014_bib6) 1991; 311
Okakura-Mochizuki (10.1016/j.neuropharm.2009.11.014_bib20) 1996; 67
Danysz (10.1016/j.neuropharm.2009.11.014_bib5) 1988; 27
Moghaddam (10.1016/j.neuropharm.2009.11.014_bib18) 1998; 281
Nakai (10.1016/j.neuropharm.2009.11.014_bib19) 1991; 30
Faucard (10.1016/j.neuropharm.2009.11.014_bib7) 2006; 98
Schoepp (10.1016/j.neuropharm.2009.11.014_bib26) 2001; 299
Schwartz (10.1016/j.neuropharm.2009.11.014_bib28) 1991; 71
Javitt (10.1016/j.neuropharm.2009.11.014_bib11) 1991; 148
Perry (10.1016/j.neuropharm.2009.11.014_bib24) 2008; 55
Danysz (10.1016/j.neuropharm.2009.11.014_bib4) 1994; 48
10.1016/j.neuropharm.2009.11.014_bib38
Woolley (10.1016/j.neuropharm.2009.11.014_bib34) 2008; 196
Wouterlood (10.1016/j.neuropharm.2009.11.014_bib35) 1987; 406
Iwabuchi (10.1016/j.neuropharm.2009.11.014_bib10) 2005; 15
Swanson (10.1016/j.neuropharm.2009.11.014_bib32) 2003; 1003
Brown (10.1016/j.neuropharm.2009.11.014_bib2) 2001; 63
Spooren (10.1016/j.neuropharm.2009.11.014_bib30) 2000; 397
Stevens (10.1016/j.neuropharm.2009.11.014_bib31) 1999; 11
Lorrain (10.1016/j.neuropharm.2009.11.014_bib16) 2003; 28
Coyle (10.1016/j.neuropharm.2009.11.014_bib3) 2004; 68
Moghaddam (10.1016/j.neuropharm.2009.11.014_bib17) 1997; 17
References_xml – volume: 326
  start-page: 209
  year: 2008
  end-page: 231
  ident: bib8
  article-title: Evidence for the role of mGlu2 not mGlu3 receptors in the pre-clinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 30
  start-page: 349
  year: 1991
  end-page: 356
  ident: bib19
  article-title: Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia
  publication-title: Biol. Psychiatry
– reference: Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates. San Diego, Academic Press.
– volume: 235
  start-page: 788
  year: 1985
  end-page: 792
  ident: bib9
  article-title: Phencyclidine and the dynamics of mouse brain histamine
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 67
  start-page: 171
  year: 1996
  end-page: 176
  ident: bib20
  article-title: Endogenous GABA modulates histamine release from the anterior hypothalamus of the rat
  publication-title: J. Neurochem.
– volume: 1003
  start-page: 309
  year: 2003
  end-page: 317
  ident: bib32
  article-title: A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists
  publication-title: Ann. N. Y. Acad. Sci.
– volume: 27
  start-page: 653
  year: 1988
  end-page: 656
  ident: bib5
  article-title: Learning impairment in rats by N-methyl-D-aspartate receptor antagonists
  publication-title: Neuropharmacology
– volume: 117
  start-page: 697
  year: 2003
  end-page: 706
  ident: bib15
  article-title: Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268
  publication-title: Neuroscience
– volume: 196
  start-page: 431
  year: 2008
  end-page: 440
  ident: bib34
  article-title: The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity
  publication-title: Psychopharmacology (Berl)
– volume: 148
  start-page: 1301
  year: 1991
  end-page: 1308
  ident: bib11
  article-title: Recent advances in the phencyclidine model of schizophrenia
  publication-title: Am. J. Psychiatry
– volume: 28
  start-page: 1622
  year: 2003
  end-page: 1632
  ident: bib16
  article-title: Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge
  publication-title: Neuropsychopharmacology
– volume: 13
  start-page: 1102
  year: 2007
  end-page: 1107
  ident: bib23
  article-title: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial
  publication-title: Nat. Med.
– volume: 48
  start-page: 111
  year: 1994
  end-page: 118
  ident: bib4
  article-title: Glutamate antagonists have different effects on spontaneous locomotor activity in rats
  publication-title: Pharmacol. Biochem. Behav.
– volume: 18
  start-page: 4705
  year: 1998
  end-page: 4721
  ident: bib29
  article-title: Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat
  publication-title: J. Neurosci.
– volume: 406
  start-page: 330
  year: 1987
  end-page: 336
  ident: bib35
  article-title: Projection from the prefrontal cortex to histaminergic cell groups in the posterior hypothalamic region of the rat. Anterograde tracing with
  publication-title: Brain Res.
– volume: 98
  start-page: 1487
  year: 2006
  end-page: 1496
  ident: bib7
  article-title: N-methyl-D-aspartate receptor antagonists enhance histamine neuron activity in rodent brain
  publication-title: J. Neurochem.
– volume: 17
  start-page: 2921
  year: 1997
  end-page: 2927
  ident: bib17
  article-title: Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to sopaminergic and cognitive disruptions associated with the prefrontal cortex
  publication-title: J. Neurosci.
– volume: 14
  start-page: 93
  year: 1995
  end-page: 104
  ident: bib25
  article-title: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms
  publication-title: Schizophr. Res.
– volume: 63
  start-page: 637
  year: 2001
  end-page: 672
  ident: bib2
  article-title: The physiology of brain histamine
  publication-title: Prog. Neurobiol.
– volume: 129
  start-page: 115
  year: 2000
  end-page: 123
  ident: bib21
  article-title: Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine
  publication-title: Br. J. Pharmacol.
– volume: 311
  start-page: 45
  year: 1991
  end-page: 64
  ident: bib6
  article-title: Origin of neuronal inputs to the region of the tuberomammillary nucleus of the rat brain
  publication-title: J. Comp. Neurol.
– volume: 759
  start-page: 205
  year: 1997
  end-page: 212
  ident: bib14
  article-title: Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex
  publication-title: Brain Res.
– volume: 68
  start-page: 1507
  year: 2004
  end-page: 1514
  ident: bib3
  article-title: The GABA-glutamate connection in schizophrenia: which is the proximate cause?
  publication-title: Biochem. Pharmacol.
– volume: 397
  start-page: R1
  year: 2000
  ident: bib30
  article-title: Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice
  publication-title: Eur. J. Pharmacol.
– volume: 43
  start-page: 238
  year: 2002
  end-page: 243
  ident: bib33
  article-title: Evidence for activation of histamine H3 autoreceptors during handling stress in the prefrontal cortex of the rat
  publication-title: Synapse
– volume: 341
  start-page: 45
  year: 1998
  end-page: 56
  ident: bib37
  article-title: Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex
  publication-title: Eur. J. Pharmacol.
– volume: 22
  start-page: 2519
  year: 2005
  end-page: 2530
  ident: bib1
  article-title: Projections from the hippocampal region to the mammillary bodies in macaque monkeys
  publication-title: Eur. J. Neurosci.
– volume: 773
  start-page: 162
  year: 1997
  end-page: 172
  ident: bib36
  article-title: Electrophysiology of excitatory and inhibitory afferents to rat histaminergic tuberomammillary nucleus neurons from hypothalamic and forebrain sites
  publication-title: Brain Res.
– volume: 55
  start-page: 743
  year: 2008
  end-page: 754
  ident: bib24
  article-title: Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas
  publication-title: Neuropharmacology
– volume: 419
  start-page: 205
  year: 2000
  end-page: 222
  ident: bib12
  article-title: Topographical organization of projections from the subiculum to the hypothalamus in the rat
  publication-title: J. Comp. Neurol.
– volume: 299
  start-page: 12
  year: 2001
  end-page: 20
  ident: bib26
  article-title: Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 83
  start-page: 945
  year: 1999
  end-page: 947
  ident: bib13
  article-title: Inhibitory effect of clonidine on ketamine-induced norepinephrine release from the medial prefrontal cortex in rats
  publication-title: Br. J. Anaesth.
– volume: 281
  start-page: 1349
  year: 1998
  end-page: 1352
  ident: bib18
  article-title: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
  publication-title: Science
– volume: 29
  start-page: 1111
  year: 1990
  end-page: 1116
  ident: bib22
  article-title: Excitatory amino acid antagonists and memory: effect of drugs acting at
  publication-title: Neuropharmacology
– volume: 15
  start-page: 185
  year: 2005
  end-page: 191
  ident: bib10
  article-title: Histamine H1 receptors in schizophrenic patients measured by positron emission tomography
  publication-title: Eur. Neuropsychopharmacol.
– volume: 1
  start-page: 215
  year: 2002
  end-page: 225
  ident: bib27
  article-title: Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?
  publication-title: Curr. Drug Targets CNS Neurol. Disord.
– volume: 71
  start-page: 1
  year: 1991
  end-page: 51
  ident: bib28
  article-title: Histaminergic transmission in the mammalian brain
  publication-title: Physiol. Rev.
– volume: 11
  start-page: 1148
  year: 1999
  end-page: 1154
  ident: bib31
  article-title: GABAB-receptor-mediated control of GABAergic inhibition in rat histaminergic neurons in vitro
  publication-title: Eur. J. Neurosci.
– volume: 14
  start-page: 93
  year: 1995
  ident: 10.1016/j.neuropharm.2009.11.014_bib25
  article-title: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms
  publication-title: Schizophr. Res.
  doi: 10.1016/0920-9964(94)00034-6
– volume: 419
  start-page: 205
  year: 2000
  ident: 10.1016/j.neuropharm.2009.11.014_bib12
  article-title: Topographical organization of projections from the subiculum to the hypothalamus in the rat
  publication-title: J. Comp. Neurol.
  doi: 10.1002/(SICI)1096-9861(20000403)419:2<205::AID-CNE5>3.0.CO;2-0
– volume: 55
  start-page: 743
  year: 2008
  ident: 10.1016/j.neuropharm.2009.11.014_bib24
  article-title: Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas
  publication-title: Neuropharmacology
  doi: 10.1016/j.neuropharm.2008.06.016
– volume: 326
  start-page: 209
  year: 2008
  ident: 10.1016/j.neuropharm.2009.11.014_bib8
  article-title: Evidence for the role of mGlu2 not mGlu3 receptors in the pre-clinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.108.136861
– volume: 17
  start-page: 2921
  year: 1997
  ident: 10.1016/j.neuropharm.2009.11.014_bib17
  article-title: Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to sopaminergic and cognitive disruptions associated with the prefrontal cortex
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.17-08-02921.1997
– volume: 406
  start-page: 330
  year: 1987
  ident: 10.1016/j.neuropharm.2009.11.014_bib35
  article-title: Projection from the prefrontal cortex to histaminergic cell groups in the posterior hypothalamic region of the rat. Anterograde tracing with Phaseolus vulgaris leucoagglutinin combined with immunocytochemistry of histidine decarboxylase
  publication-title: Brain Res.
  doi: 10.1016/0006-8993(87)90802-X
– volume: 29
  start-page: 1111
  year: 1990
  ident: 10.1016/j.neuropharm.2009.11.014_bib22
  article-title: Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-d-aspartate receptors in learning and memory tasks
  publication-title: Neuropharmacology
  doi: 10.1016/0028-3908(90)90034-O
– volume: 129
  start-page: 115
  year: 2000
  ident: 10.1016/j.neuropharm.2009.11.014_bib21
  article-title: Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine
  publication-title: Br. J. Pharmacol.
  doi: 10.1038/sj.bjp.0702994
– volume: 397
  start-page: R1
  year: 2000
  ident: 10.1016/j.neuropharm.2009.11.014_bib30
  article-title: Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/S0014-2999(00)00269-7
– volume: 28
  start-page: 1622
  year: 2003
  ident: 10.1016/j.neuropharm.2009.11.014_bib16
  article-title: Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge
  publication-title: Neuropsychopharmacology
  doi: 10.1038/sj.npp.1300238
– volume: 48
  start-page: 111
  year: 1994
  ident: 10.1016/j.neuropharm.2009.11.014_bib4
  article-title: Glutamate antagonists have different effects on spontaneous locomotor activity in rats
  publication-title: Pharmacol. Biochem. Behav.
  doi: 10.1016/0091-3057(94)90506-1
– volume: 311
  start-page: 45
  year: 1991
  ident: 10.1016/j.neuropharm.2009.11.014_bib6
  article-title: Origin of neuronal inputs to the region of the tuberomammillary nucleus of the rat brain
  publication-title: J. Comp. Neurol.
  doi: 10.1002/cne.903110105
– volume: 13
  start-page: 1102
  year: 2007
  ident: 10.1016/j.neuropharm.2009.11.014_bib23
  article-title: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial
  publication-title: Nat. Med.
  doi: 10.1038/nm1632
– volume: 15
  start-page: 185
  year: 2005
  ident: 10.1016/j.neuropharm.2009.11.014_bib10
  article-title: Histamine H1 receptors in schizophrenic patients measured by positron emission tomography
  publication-title: Eur. Neuropsychopharmacol.
  doi: 10.1016/j.euroneuro.2004.10.001
– volume: 759
  start-page: 205
  year: 1997
  ident: 10.1016/j.neuropharm.2009.11.014_bib14
  article-title: Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex
  publication-title: Brain Res.
  doi: 10.1016/S0006-8993(97)00255-2
– volume: 117
  start-page: 697
  year: 2003
  ident: 10.1016/j.neuropharm.2009.11.014_bib15
  article-title: Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268
  publication-title: Neuroscience
  doi: 10.1016/S0306-4522(02)00652-8
– volume: 83
  start-page: 945
  year: 1999
  ident: 10.1016/j.neuropharm.2009.11.014_bib13
  article-title: Inhibitory effect of clonidine on ketamine-induced norepinephrine release from the medial prefrontal cortex in rats
  publication-title: Br. J. Anaesth.
  doi: 10.1093/bja/83.6.945
– volume: 67
  start-page: 171
  year: 1996
  ident: 10.1016/j.neuropharm.2009.11.014_bib20
  article-title: Endogenous GABA modulates histamine release from the anterior hypothalamus of the rat
  publication-title: J. Neurochem.
  doi: 10.1046/j.1471-4159.1996.67010171.x
– volume: 1
  start-page: 215
  year: 2002
  ident: 10.1016/j.neuropharm.2009.11.014_bib27
  article-title: Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?
  publication-title: Curr. Drug Targets CNS Neurol. Disord.
  doi: 10.2174/1568007024606177
– volume: 196
  start-page: 431
  year: 2008
  ident: 10.1016/j.neuropharm.2009.11.014_bib34
  article-title: The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/s00213-007-0974-x
– volume: 43
  start-page: 238
  year: 2002
  ident: 10.1016/j.neuropharm.2009.11.014_bib33
  article-title: Evidence for activation of histamine H3 autoreceptors during handling stress in the prefrontal cortex of the rat
  publication-title: Synapse
  doi: 10.1002/syn.10043
– volume: 1003
  start-page: 309
  year: 2003
  ident: 10.1016/j.neuropharm.2009.11.014_bib32
  article-title: A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists
  publication-title: Ann. N. Y. Acad. Sci.
  doi: 10.1196/annals.1300.019
– volume: 281
  start-page: 1349
  year: 1998
  ident: 10.1016/j.neuropharm.2009.11.014_bib18
  article-title: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
  publication-title: Science
  doi: 10.1126/science.281.5381.1349
– volume: 30
  start-page: 349
  year: 1991
  ident: 10.1016/j.neuropharm.2009.11.014_bib19
  article-title: Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia
  publication-title: Biol. Psychiatry
  doi: 10.1016/0006-3223(91)90290-3
– volume: 11
  start-page: 1148
  year: 1999
  ident: 10.1016/j.neuropharm.2009.11.014_bib31
  article-title: GABAB-receptor-mediated control of GABAergic inhibition in rat histaminergic neurons in vitro
  publication-title: Eur. J. Neurosci.
  doi: 10.1046/j.1460-9568.1999.00519.x
– volume: 299
  start-page: 12
  year: 2001
  ident: 10.1016/j.neuropharm.2009.11.014_bib26
  article-title: Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system
  publication-title: J. Pharmacol. Exp. Ther.
– ident: 10.1016/j.neuropharm.2009.11.014_bib38
– volume: 341
  start-page: 45
  year: 1998
  ident: 10.1016/j.neuropharm.2009.11.014_bib37
  article-title: Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/S0014-2999(97)01435-0
– volume: 235
  start-page: 788
  year: 1985
  ident: 10.1016/j.neuropharm.2009.11.014_bib9
  article-title: Phencyclidine and the dynamics of mouse brain histamine
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 68
  start-page: 1507
  year: 2004
  ident: 10.1016/j.neuropharm.2009.11.014_bib3
  article-title: The GABA-glutamate connection in schizophrenia: which is the proximate cause?
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2004.07.034
– volume: 27
  start-page: 653
  year: 1988
  ident: 10.1016/j.neuropharm.2009.11.014_bib5
  article-title: Learning impairment in rats by N-methyl-D-aspartate receptor antagonists
  publication-title: Neuropharmacology
  doi: 10.1016/0028-3908(88)90189-X
– volume: 71
  start-page: 1
  year: 1991
  ident: 10.1016/j.neuropharm.2009.11.014_bib28
  article-title: Histaminergic transmission in the mammalian brain
  publication-title: Physiol. Rev.
  doi: 10.1152/physrev.1991.71.1.1
– volume: 63
  start-page: 637
  year: 2001
  ident: 10.1016/j.neuropharm.2009.11.014_bib2
  article-title: The physiology of brain histamine
  publication-title: Prog. Neurobiol.
  doi: 10.1016/S0301-0082(00)00039-3
– volume: 773
  start-page: 162
  year: 1997
  ident: 10.1016/j.neuropharm.2009.11.014_bib36
  article-title: Electrophysiology of excitatory and inhibitory afferents to rat histaminergic tuberomammillary nucleus neurons from hypothalamic and forebrain sites
  publication-title: Brain Res.
  doi: 10.1016/S0006-8993(97)00932-3
– volume: 18
  start-page: 4705
  year: 1998
  ident: 10.1016/j.neuropharm.2009.11.014_bib29
  article-title: Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.18-12-04705.1998
– volume: 22
  start-page: 2519
  year: 2005
  ident: 10.1016/j.neuropharm.2009.11.014_bib1
  article-title: Projections from the hippocampal region to the mammillary bodies in macaque monkeys
  publication-title: Eur. J. Neurosci.
  doi: 10.1111/j.1460-9568.2005.04450.x
– volume: 98
  start-page: 1487
  year: 2006
  ident: 10.1016/j.neuropharm.2009.11.014_bib7
  article-title: N-methyl-D-aspartate receptor antagonists enhance histamine neuron activity in rodent brain
  publication-title: J. Neurochem.
  doi: 10.1111/j.1471-4159.2006.04002.x
– volume: 148
  start-page: 1301
  year: 1991
  ident: 10.1016/j.neuropharm.2009.11.014_bib11
  article-title: Recent advances in the phencyclidine model of schizophrenia
  publication-title: Am. J. Psychiatry
  doi: 10.1176/ajp.148.10.1301
SSID ssj0004818
Score 2.0876653
Snippet In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain....
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 632
SubjectTerms Amino Acids - pharmacology
Analysis of Variance
Animals
Bridged Bicyclo Compounds, Heterocyclic - pharmacology
CBiPES
Cyclopropanes - pharmacology
Dose-Response Relationship, Drug
Drug Interactions
Electrochemistry - methods
Excitatory Amino Acid Agonists - pharmacology
Excitatory Amino Acid Antagonists - pharmacology
Histamine
Histamine - metabolism
In vivo microdialysis
Indoles - pharmacology
Ketamine
Ketamine - pharmacology
Limbic System - anatomy & histology
Limbic System - drug effects
Limbic System - metabolism
LY379268
Male
mGlu2/3 receptors
Microdialysis - methods
Quinoxalines - pharmacology
Rats
Rats, Sprague-Dawley
Receptors, Metabotropic Glutamate - agonists
Receptors, Metabotropic Glutamate - antagonists & inhibitors
Receptors, Metabotropic Glutamate - metabolism
Title Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge
URI https://dx.doi.org/10.1016/j.neuropharm.2009.11.014
https://www.ncbi.nlm.nih.gov/pubmed/19951716
https://www.proquest.com/docview/21298134
https://www.proquest.com/docview/733858511
Volume 58
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwELUQXLigQqHd8tE5IEQlApvEiR1xWqHShaqIA0jcothxqrS72YhNhPbCT-A3MxMnRD2shNRrZEdWPJ55Vt68x9ihJ1zPhEPppInQDpc8cGQQDYnTkAolNA8lNTj_ugnH9_z6IXhYYRddLwzRKtvcb3N6k63bJ2ft1zwr85x6fLE0Roh4okZUpelg54Ki_PS5p3lw6cpOiZlGt2wey_FqNCNL0oi2ypWk5-nyZSVqGQRtStHlB7bRYkgY2WVushVTbLGjWytCvTiBu76nan4CR3Dby1MvPrKXke4szWCWwdRUGAcVLjDX8BvjMEEMa-B4-mNSf_MAP44pyZEH5nXZkGbNHEikOJkiPgWyXME6CHkBk3yq8BWKPCeA_B4wniHDMJs9YXmERNf42r-mnag7E5dtdn_5_e5i7LSuDI7mYlg5xos4idphbsBaL1U49IXQiAJ0lmVch3ih8Q1XYcIVHu6AHDi14kpk2rh4XeP-DlstZoX5zECpANND6go_CXgaeSpFAEJ6-iqQiGv4gIluI2LdSpaTc8Yk7rhpf-J-C8lRM8IbTYxbOGDu28zSyna8Y855t9fxPyEYY3V5x-yvXXjEeELpt0tSmFk9jxEcRNL1cQQsGSF8-3vWHbBPNrD6RUcIgfFO--W_FrfL1i3rgbhze2y1eqzNPoKpSh00p-WArY2ufo5vXgGzQCHi
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwELUQHOBStaW02y_mUCGQSNkkTuyoJ4QKSwuIwyJxs2LHqdLuZqNuoooLP4HfzEycNOphJaReIzuy4vHMG-X5PcY-BcIPbDyWXpYK43HJI09GyZg4DZnQwvBY0gXny6t4csO_3Ua3a-ykvwtDtMou97uc3mbr7slR9zWPqqKgO75YGhNEPEkrqoIt0AbH40s2Bp_vB54Hl77spZhpeEfncSSvVjSyIpFoJ11Jgp4-X1WjVmHQthadPmfPOhAJx26dL9iaLV-yvWunQn13CNPhUtXyEPbgetCnvttmD8em9zSDRQ5zW2Mg1LjAwsAPDMQUQayF_fnZrDkIAL-OrciSB5ZN1bJm7RJIpTidI0AF8lzBQghFCbNirvEVmkwngAwfMKAhxzhb_MH6CKlp8LW_bDfR9C4ur9jN6dfpycTrbBk8w8W49myQcFK1w-SAxV7qeBwKYRAGmDzPuYmxowkt13HKNZ7uiCw4jeZa5Mb62K_xcIetl4vSvmGgdYT5IfNFmEY8SwKdIQIhQX0dSQQ2fMREvxHKdJrlZJ0xUz057acatpAsNRNsaRRu4Yj5f2dWTrfjCXO-9Hut_olBheXlCbN3-_BQeETpv0ta2kWzVIgOEumHOAJWjBCh-z_rj9hrF1jDohPEwNjUvv2vxe2yzcn08kJdnF99f8e2HAWCiHTv2Xr9u7EfEFnV-mN7ch4BFrEjcA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Activation+of+metabotropic+glutamate+%28mGlu%292+receptors+suppresses+histamine+release+in+limbic+brain+regions+following+acute+ketamine+challenge&rft.jtitle=Neuropharmacology&rft.au=Fell%2C+Matthew+J&rft.au=Katner%2C+Jason+S&rft.au=Johnson%2C+Bryan+G&rft.au=Khilevich%2C+Albert&rft.date=2010-03-01&rft.issn=1873-7064&rft.eissn=1873-7064&rft.volume=58&rft.issue=3&rft.spage=632&rft_id=info:doi/10.1016%2Fj.neuropharm.2009.11.014&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-3908&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-3908&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-3908&client=summon